ProMIS Neurosciences, Inc. (PMN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$10.35
Price Target
$18.00
Target Range
$18.00 — $18.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-0.5x
Forward PEG—
Implied Growth-1.4%
Median Target$18.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$18
+73.9%
Consensus
$18
+73.9%
Bull Case
$18
+73.9%
PMN Price Target Analysis
Updated June 13, 2026As of June 13, 2026, ProMIS Neurosciences, Inc. (PMN) has a Wall Street consensus price target of $18.00, based on estimates from 2 covering analysts. With the stock currently trading at $10.35, this represents a potential upside of +73.9%. The company has a market capitalization of $68M.
Analyst price targets range from a low of $18.00 to a high of $18.00, representing a 0% spread in expectations. The median target of $18.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PMN trades at a trailing P/E of -0.5x. Analysts expect EPS to grow -1.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+52.0%
Avg Forward P/E62.6x
Peers with Coverage8 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRTAProthena Corporation plc | $432M | $8.25 | $19.00 | +130.3% | Buy | 176.7x | 28 |
 ARVNArvinas, Inc. | $489M | $7.58 | $14.75 | +94.6% | Buy | — | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.09 | $34.78 | +64.9% | Buy | 54.2x | 37 |
 SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
 NRXPNRx Pharmaceuticals, Inc. | $66M | $3.84 | — | — | — | — | — |
 BIIBBiogen Inc. | $29.5B | $200.05 | $218.16 | +9.1% | Buy | 13.7x | 48 |
 LLYEli Lilly and Company | $1.1T | $1133.00 | $1268.94 | +12.0% | Buy | 30.9x | 45 |
 ESPREsperion Therapeutics, Inc. | $655M | $3.15 | $3.19 | +1.3% | Hold | — | 25 |
 IONSIonis Pharmaceuticals, Inc. | $12.1B | $73.28 | $107.27 | +46.4% | Buy | — | 32 |
 ALNYAlnylam Pharmaceuticals, Inc. | $37.7B | $282.85 | $445.67 | +57.6% | Buy | 37.7x | 52 |
Upside Potential Comparison
PRTAARVNACADALNYIONSLLYBIIBESPRWhat if you invested $1,000 in PMN 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PMN be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PMN Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPMN vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPMN — Frequently Asked Questions
Quick answers to the most common questions about buying PMN stock.
What is the PMN stock price target for 2026?
The consensus Wall Street price target for PMN is $18, representing 73.9% upside from the current price of $10.35. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PMN a buy, sell, or hold?
PMN has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $18 implies 73.9% upside from current levels.
Is PMN stock overvalued or undervalued?
PMN's current price is $10.35 with a consensus target of $18 (73.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can PMN stock go?
The most bullish Wall Street analyst has a price target of $18 for PMN, while the most conservative target is $18. The consensus of $18 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PMN stock?
PMN is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PMN stock forecast?
The 12-month PMN stock forecast based on 2 Wall Street analysts shows a consensus price target of $18, with estimates ranging from $18 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Should I buy PMN stock?
Wall Street analysts are very optimistic on PMN, with a "Buy" consensus rating and $18 price target (73.9% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PMN price targets vary so much?
PMN analyst price targets range from $18 to $18, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18 consensus represents the middle ground.